IVIG Administration in Neonatal Hemolytic Disease with Rising Bilirubin

Assessment and Indications

• The American Academy of Pediatrics recommends IVIG administration in isoimmune hemolytic disease when total serum bilirubin (TSB) is rising despite intensive phototherapy, or when TSB level is within 2-3 mg/dL of the exchange transfusion threshold, with a dose of 0.5-1 g/kg over 2 hours 1, 2, 4
• A rate of rise of TSB of ≥0.2 mg/dL per hour suggests ongoing hemolysis, indicating the need for IVIG therapy in a neonate with Rh incompatibility 3

Recommended IVIG Protocol and Monitoring

• Administer IVIG at a dose of 0.5-1 g/kg over 2 hours, and consider repeating the dose in 12 hours if necessary, with concurrent intensive phototherapy 1, 2, 5
• Monitor TSB every 2-3 hours given high and rising levels, and watch for signs of acute bilirubin encephalopathy 1, 5, 6

Expected Outcomes

• IVIG has been shown to reduce the need for exchange transfusion in Rh hemolytic disease, with the American Academy of Pediatrics recommending its use in cases with documented ongoing hemolysis despite phototherapy 1, 2
• If TSB continues to rise despite IVIG and intensive phototherapy, prepare for possible exchange transfusion, with the American Academy of Pediatrics guidelines supporting the use of IVIG in such cases 1, 2